Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Autologous T Cells Modified With ILT3 Chimeric Antigen Receptor for Relapsed/Refractory Acute Myeloid Leukemia (M4/M5)

NCT04803929 is registered in ClinicalTrials.gov with Carbiogene Therapeutics Co. Ltd. as lead sponsor.

NCT NCT04803929
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04803929 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Autologous T Cells Modified With ILT3 Chimeric Antigen Receptor for Relapsed/Refractory Acute Myeloid Leukemia (M4/M5)
Lead sponsor
Carbiogene Therapeutics Co. Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
March 3, 2021
Completion date
March 1, 2026
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml m4, aml m5